Remarkably, CPI‐613 was identified as one of the top 10 drugs showing significant differences in sensitivity between HPV‐ HNSCC cases with mutant FAT1 and those with wild‐type FAT1 (Figure 4B). The gene discussed is FAT1; the disease is head and neck squamous cell carcinoma.